Bremelanotide Has Completed Randomised Trials. A 2026 Review Found Their Safety Reporting Inconsistent.

Most safety writing on this site has to work around an absence: there is no completed trial, so there is no safety record to examine. PT-141 is one of the exceptions, and that makes it worth examining for a different reason.

What PT-141 is

PT-141 is bremelanotide, a cyclic heptapeptide that activates melanocortin receptors. Unlike most of the compounds discussed alongside it, it acts centrally, in the brain, rather than on blood flow — and unlike most of them, it finished clinical development. It was approved by the FDA in 2019, under the brand name Vyleesi, for acquired, generalised hypoactive sexual desire disorder in premenopausal women.

So here is a compound in this library that went the whole regulated route: registered trials, placebo controls, a marketing application, a label. The question this article asks is what that record looks like when someone goes back and reads all of it together.

The review

A systematic review published in Frontiers in Medicine on 22 May 2026, by Ahmed M. Ashour at Umm Al-Qura University, did exactly that. It followed PRISMA 2020 guidelines and searched ClinicalTrials.gov for completed interventional trials of pharmacological therapies for hypoactive sexual desire disorder in adult women.

Nine completed trials met the inclusion criteria. Most were phase 2 and phase 3 randomised, double-blind, placebo-controlled studies, enrolling mainly premenopausal women with acquired, generalised HSDD. Across that set, flibanserin and bremelanotide were the two most extensively studied agents.

Efficacy was generally measured with validated patient-reported instruments — the desire domain of the Female Sexual Function Index, and the Female Sexual Distress Scale. But the reviewer notes that endpoint designation and reporting completeness varied across trials.

The finding this article is about

In the review's own words: safety data were inconsistently reported, with adverse events reflecting the pharmacological mechanisms of the agents studied.

It is worth being precise about what that does and does not mean, because this is exactly the kind of sentence that gets stretched in both directions.

It is not a finding of harm. The review reports no safety signal, identifies no adverse outcome, and does not claim any agent was shown to be dangerous. Inconsistent reporting is a statement about the papers, not about the compounds.

What it does mean is that the nine trials did not describe their safety results in a common way — so the set cannot be read as one body of evidence on harm. You cannot add them up. The reviewer's own conclusion says as much: variability in trial design, outcome measures and reporting practices limits cross-trial comparison and clinical interpretation.

Why that is the useful finding

Take the two halves of this field and put them next to each other.

On one side, a compound that completed registered, placebo-controlled, phase 3 development and carries an approved label. Even there, a reviewer going back through the completed trials finds the safety reporting uneven enough that the studies resist being compared.

On the other side sits nearly everything else this publication covers — compounds with no completed trial at all. The September 2026 narrative review in Sexual Medicine Reviews, which surveyed peptides used in urology and sexual medicine, placed bremelanotide among the small group of clinically established agents with defined regulatory approval, and found that across the other peptide classes safety data were limited by short follow-up, small samples, and incomplete assessment of cardiovascular, metabolic and oncologic outcomes.

The comparison is the point. If the most thoroughly documented corner of this space still has gaps a systematic reviewer can find, the undocumented corner does not have a safety record that is merely thinner. It does not have one.

The indication is narrow, and that matters

One more distinction worth holding. The approval is for a specific diagnosis in a specific population: acquired, generalised HSDD in premenopausal women. The nine trials in this review enrolled that population.

Research into the melanocortin pathway is a much wider subject than that indication, and nothing in this trial set speaks to melanocortin-receptor activity outside it. A record built in one population, for one diagnosis, under one regulatory submission, is evidence about that — and about nothing else.

What has not been studied

• No trial in this review evaluated bremelanotide outside the HSDD indication or outside its enrolled population.
• The review synthesised findings descriptively and did not pool data, so it produces no quantitative estimate of adverse-event rates.
• Long-term safety beyond the durations of the included trials is not characterised in this review.
• Material obtained outside a regulated supply chain is not the product these trials studied, and no trial evidence transfers to it. Identity, purity and concentration are unverified in that setting.

What to watch

The reviewer calls for standardised methodologies and comprehensive reporting in future trials, which is the kind of recommendation that is easy to agree with and slow to take effect.

The more useful thing to watch is narrower: whether any new trial in this space publishes its safety results in a form that lets a reader compare them to the trials that came before. That is a low bar. This review found that nine completed, registered, mostly placebo-controlled studies had not cleared it.

Sources

1. Ashour AM. Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov. Front Med (Lausanne) (2026)
2. Vasylieva V, West A, Karpman E. Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review. Sex Med Rev (2026)

Compounds in this article

PT-141